Asymmetric Dimethylarginine and Reactive Oxygen Species: Unwelcome Twin Visitors to the Cardiovascular and Kidney Disease Tables

Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause...

Full description

Saved in:
Bibliographic Details
Published inHypertension (Dallas, Tex. 1979) Vol. 59; no. 2 Suppl 1; pp. 375 - 381
Main Author Wilcox, Christopher S.
Format Journal Article
LanguageEnglish
Published Hagerstown, MD American Heart Association, Inc 01.02.2012
Lippincott Williams & Wilkins
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22 had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease.
AbstractList Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22 phox had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease.
Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22(phox) had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease.Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22(phox) had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease.
Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22(phox) had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease.
Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22 had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease.
Author Wilcox, Christopher S.
AuthorAffiliation From the Division of Nephrology and Hypertension and Hypertension, Kidney, and Vascular Research Center, Georgetown University, Washington, DC
AuthorAffiliation_xml – name: From the Division of Nephrology and Hypertension and Hypertension, Kidney, and Vascular Research Center, Georgetown University, Washington, DC
Author_xml – sequence: 1
  givenname: Christopher
  surname: Wilcox
  middlename: S.
  fullname: Wilcox, Christopher S.
  organization: From the Division of Nephrology and Hypertension and Hypertension, Kidney, and Vascular Research Center, Georgetown University, Washington, DC
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25493495$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22215715$$D View this record in MEDLINE/PubMed
BookMark eNqNks1uEzEUhS1URNPCKyALCbGa4t_JuCuiEEhF1aA2RbAaOZ7rxuDxBHvSkB2PjkMCSF3hja2j75wr-_gEHYUuAEIvKDmjtKSvp18-Tq7nk6ubi9nVaDrKIj2j1ZBT8ggNqGSiELLkR2hAqBKFovTzMTpJ6SshVAgxfIKOGWNUDqkcoJ-jtG1b6KMz-K3Lh-XW63jngguAdWjwNWjTu3vAsx_bOwj4ZgXGQTrHt2ED3nQt4PnGBfzJJdd3MeG-w_0S8FjHxnX3Opl1Dvwd9cE1AbZ5TAKdsk0vPKSn6LHVPsGzw36Kbt9N5uNpcTl7fzEeXRaGK84L1ljDlBaMUlFZ0TSkspJTKa2x1lSSgGCNMQupF2VlbSktU6VcNFbJqizB8FP0ap-7it33NaS-bl0y4L0O0K1TrWhFuFRKZPL5gVwvWmjqVXStjtv6z6Nl4OUByLfT3kYdjEv_OCkUF2rHne85E7uUIti_CCX1rsn6QZNZpPW-yWx-88BsXK9714U-auf_L0LsIzad7yGmb369gVgvQft-WZO8BCurghHKCMufo9hJnP8CLXe4_Q
CODEN HPRTDN
CitedBy_id crossref_primary_10_1016_j_jacadv_2025_101590
crossref_primary_10_1093_ndt_gfv380
crossref_primary_10_1093_ajh_hpu129
crossref_primary_10_1161_CIRCRESAHA_121_318082
crossref_primary_10_1042_CS20210566
crossref_primary_10_1093_ndt_gfy174
crossref_primary_10_1016_j_physbeh_2020_113295
crossref_primary_10_1038_s41440_018_0122_5
crossref_primary_10_1093_ndt_gfu219
crossref_primary_10_3389_fphys_2014_00292
crossref_primary_10_1016_j_niox_2013_02_080
crossref_primary_10_1186_s12882_015_0162_x
crossref_primary_10_1007_s00726_015_2096_9
crossref_primary_10_1074_jbc_M115_651380
crossref_primary_10_1016_j_ejphar_2012_09_019
crossref_primary_10_1016_j_niox_2017_04_002
crossref_primary_10_1097_PEC_0000000000001339
crossref_primary_10_1007_s12668_024_01617_4
crossref_primary_10_2478_jomb_2018_0025
crossref_primary_10_3389_fphys_2014_00531
crossref_primary_10_3390_jcm9093026
crossref_primary_10_1016_j_bbrep_2017_04_017
crossref_primary_10_1152_ajprenal_00045_2012
crossref_primary_10_3109_10715762_2015_1006215
crossref_primary_10_1016_j_transproceed_2014_12_014
crossref_primary_10_1016_j_trsl_2014_07_006
crossref_primary_10_1016_j_bas_2023_101745
crossref_primary_10_3389_fimmu_2022_918241
crossref_primary_10_1016_j_jstrokecerebrovasdis_2020_105376
crossref_primary_10_1016_j_bbrc_2015_08_043
crossref_primary_10_1016_j_biopha_2025_117958
crossref_primary_10_1016_j_biopha_2018_07_096
crossref_primary_10_1161_CIRCULATIONAHA_115_017923
crossref_primary_10_3390_metabo13020266
crossref_primary_10_15171_jarcm_2015_037
crossref_primary_10_1089_ars_2020_8184
crossref_primary_10_1152_ajpregu_00122_2017
crossref_primary_10_1161_CIRCRESAHA_116_302855
crossref_primary_10_1016_j_pharmthera_2013_07_004
crossref_primary_10_1016_j_semnephrol_2014_08_004
crossref_primary_10_1038_s41397_019_0082_4
crossref_primary_10_1093_ehjci_jet120
crossref_primary_10_1007_s00726_014_1825_9
crossref_primary_10_3390_jcm9082359
crossref_primary_10_3889_oamjms_2021_6572
crossref_primary_10_1152_ajprenal_00560_2017
crossref_primary_10_3390_ijms18040841
crossref_primary_10_1161_HYPERTENSIONAHA_114_04760
crossref_primary_10_3390_diagnostics13162709
crossref_primary_10_3390_antiox11050845
crossref_primary_10_3390_ijms14048062
crossref_primary_10_1111_bph_13380
crossref_primary_10_1371_journal_pone_0120287
crossref_primary_10_1042_CS20120074
crossref_primary_10_1111_apha_12646
crossref_primary_10_1016_j_cca_2014_11_002
crossref_primary_10_1177_0004563218822655
crossref_primary_10_3390_ijms17122020
crossref_primary_10_1007_s00394_017_1548_2
crossref_primary_10_3390_ijms140917553
Cites_doi 10.1177/1358836X0501000106
10.1016/j.vph.2005.09.005
10.1161/01.CIR.99.24.3092
10.1177/1358836X0501000104
10.1093/eurheartj/ehp061
10.1021/bi702377a
10.1093/ajh/3.3.242
10.1016/j.pharmthera.2010.01.003
10.1161/hypertensionaha.111.170472
10.1038/sj.ki.5001983
10.1152/ajpheart.00134.2002
10.2337/diacare.27.3.765
10.1161/circresaha.107.158915
10.1172/JCI200314172
10.1093/cvr/cvq366
10.1152/ajpheart.00998.2007
10.1016/0006-291X(87)90929-6
10.1042/CS20050307
10.1161/atvbaha.110.222638
10.1161/01.HYP.38.3.655
10.1124/pr.108.000240
10.1016/S0091-679X(08)60010-2
10.1016/j.freeradbiomed.2008.08.013
10.1016/0003-9861(87)90060-9
10.1161/01.cir.0000093661.90582.c4
10.1016/j.jacc.2008.04.019
10.1002/cbic.200500527
10.1172/JCI118623
10.1056/NEJMoa013591
10.1038/ncpneph0143
10.1006/niox.1996.0106
10.1161/01.hyp.0000156746.25300.1c
10.1161/01.atv.0000128897.54893.26
10.1152/ajprenal.00423.2003
10.1016/j.freeradbiomed.2007.06.019
10.1152/ajpheart.1986.250.5.H822
10.2337/db06-1772
10.1161/circresaha.107.156901
10.1161/01.RES.80.1.45
10.1097/01.ASN.0000090747.59919.D2
10.1007/s11906-011-0187-x
10.1093/ndt/17.11.1999
10.1097/00005344-199204002-00018
10.1248/bpb.28.641
10.1016/S0165-6147(03)00233-5
10.1172/JCI118935
10.1161/01.CIR.98.18.1842
10.1016/j.freeradbiomed.2011.06.011
10.1111/j.1523-1755.2005.00392.x
10.1152/ajpheart.01103.2007
10.1159/000103284
10.1053/j.ajkd.2007.09.020
10.1161/ATVBAHA.108.181610
10.1074/jbc.M109.037036
10.1046/j.1365-2362.2003.01150.x
10.1161/01.hyp.0000259669.40991.1e
10.1089/ars.2006.8.1597
10.1161/hypertensionaha.110.157115
10.1016/j.freeradbiomed.2009.07.006
10.1016/j.phrs.2009.08.002
10.1016/S0895-7061(02)02278-1
10.1016/S0021-9258(18)62716-4
10.1161/hypertensionaha.109.135426
10.1161/01.RES.87.2.99
10.1046/j.1523-1755.2002.00437.x
10.1038/hr.2010.201
10.1016/S0140-6736(01)07217-8
10.1161/01.res.0000129578.76799.75
10.1161/01.hyp.0000200023.02195.73
10.1038/sj.ki.5000067
10.1152/ajpheart.00626.2004
10.1093/ndt/gfg452
10.1111/j.1476-5381.2009.00259.x
10.1161/hypertensionaha.110.152959
10.1007/s10157-008-0034-9
10.1161/01.RES.0000020404.01971.2F
10.1161/01.hyp.0000158262.11935.d0
10.1161/01.hyp.0000154365.30593.d3
10.1111/j.1523-1755.2000.00380.x
10.1161/01.hyp.0000052945.84627.8f
10.1152/ajpregu.90506.2008
10.1016/S0021-9258(18)81786-0
10.1016/j.bbrc.2004.01.120
10.1038/sj.ki.5000417
10.1161/hypertensionaha.109.142422
10.1152/ajpregu.90875.2008
10.1152/ajpregu.00250.2005
ContentType Journal Article
Copyright 2012 American Heart Association, Inc.
2015 INIST-CNRS
Copyright_xml – notice: 2012 American Heart Association, Inc.
– notice: 2015 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/HYPERTENSIONAHA.111.187310
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4563
EndPage 381
ExternalDocumentID 22215715
25493495
10_1161_HYPERTENSIONAHA_111_187310
00004268-201202001-00003
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: R01 DK036079
– fundername: NIDDK NIH HHS
  grantid: DK-049870
– fundername: NHLBI NIH HHS
  grantid: P01 HL068686
– fundername: NIAID NIH HHS
  grantid: AI-034994
– fundername: NIDDK NIH HHS
  grantid: R01 DK049870
– fundername: NIAID NIH HHS
  grantid: AI-087714
– fundername: NIDDK NIH HHS
  grantid: DK-036079
– fundername: NIAID NIH HHS
  grantid: U01 AI034994
– fundername: NHLBI NIH HHS
  grantid: HL-068686
– fundername: NIDDK NIH HHS
  grantid: R37 DK036079
GroupedDBID ---
.-D
.3C
.55
.GJ
.XZ
.Z2
01R
0R~
18M
1J1
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAFWJ
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAXQO
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABPXF
ABQRW
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACLDA
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFBFQ
AFDTB
AFEXH
AFFNX
AFNMH
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHQVU
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BAWUL
BCGUY
BOYCO
BQLVK
BS7
C1A
C45
CS3
DIK
DIWNM
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JF9
JG8
JK3
JK8
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
N4W
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB3
OCUKA
ODA
ODMTH
OGROG
OHYEH
OK1
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
R58
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
V2I
VVN
W3M
W8F
WH7
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YHZ
YOC
YYM
YYP
ZFV
ZGI
ZZMQN
AAYXX
ADGHP
CITATION
IQODW
OZ-
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c3933-2dfc29a421148f4dd08f53155fcffc850e42dccb5ab68ff65f2965bdf95866ec3
ISSN 0194-911X
1524-4563
IngestDate Mon Jul 21 09:27:16 EDT 2025
Sat May 31 02:08:10 EDT 2025
Mon Jul 21 09:13:58 EDT 2025
Thu Apr 24 22:55:08 EDT 2025
Tue Jul 01 04:30:53 EDT 2025
Fri May 16 03:51:30 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2 Suppl 1
Keywords Hypertension
NADPH
Kidney disease
endothelial function
NO
Oxygen
Urinary system disease
Enzyme
Peptide hormone
Oxidase
Cardiovascular disease
Twin
Octapeptide
NADPH oxidase
Oxidoreductases
Angiotensin II
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3933-2dfc29a421148f4dd08f53155fcffc850e42dccb5ab68ff65f2965bdf95866ec3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 22215715
PQID 918035994
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_918035994
pubmed_primary_22215715
pascalfrancis_primary_25493495
crossref_primary_10_1161_HYPERTENSIONAHA_111_187310
crossref_citationtrail_10_1161_HYPERTENSIONAHA_111_187310
wolterskluwer_health_00004268-201202001-00003
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-February
PublicationDateYYYYMMDD 2012-02-01
PublicationDate_xml – month: 02
  year: 2012
  text: 2012-February
PublicationDecade 2010
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
PublicationTitle Hypertension (Dallas, Tex. 1979)
PublicationTitleAlternate Hypertension
PublicationYear 2012
Publisher American Heart Association, Inc
Lippincott Williams & Wilkins
Publisher_xml – name: American Heart Association, Inc
– name: Lippincott Williams & Wilkins
References e_1_3_4_3_2
e_1_3_4_61_2
e_1_3_4_82_2
e_1_3_4_9_2
e_1_3_4_63_2
e_1_3_4_84_2
e_1_3_4_7_2
e_1_3_4_40_2
e_1_3_4_5_2
e_1_3_4_80_2
e_1_3_4_23_2
e_1_3_4_44_2
e_1_3_4_69_2
e_1_3_4_21_2
e_1_3_4_42_2
e_1_3_4_27_2
e_1_3_4_48_2
e_1_3_4_65_2
e_1_3_4_25_2
e_1_3_4_46_2
e_1_3_4_67_2
e_1_3_4_88_2
e_1_3_4_29_2
e_1_3_4_72_2
e_1_3_4_74_2
e_1_3_4_30_2
e_1_3_4_51_2
e_1_3_4_70_2
e_1_3_4_11_2
e_1_3_4_34_2
e_1_3_4_57_2
e_1_3_4_55_2
e_1_3_4_32_2
e_1_3_4_59_2
e_1_3_4_53_2
e_1_3_4_15_2
e_1_3_4_38_2
e_1_3_4_76_2
e_1_3_4_13_2
e_1_3_4_36_2
e_1_3_4_78_2
e_1_3_4_19_2
e_1_3_4_17_2
e_1_3_4_2_2
e_1_3_4_60_2
e_1_3_4_83_2
e_1_3_4_62_2
e_1_3_4_85_2
e_1_3_4_8_2
e_1_3_4_41_2
e_1_3_4_6_2
e_1_3_4_81_2
e_1_3_4_4_2
e_1_3_4_22_2
e_1_3_4_45_2
e_1_3_4_68_2
e_1_3_4_20_2
e_1_3_4_43_2
e_1_3_4_26_2
e_1_3_4_49_2
e_1_3_4_64_2
e_1_3_4_24_2
e_1_3_4_47_2
e_1_3_4_66_2
e_1_3_4_89_2
e_1_3_4_28_2
e_1_3_4_71_2
e_1_3_4_73_2
e_1_3_4_52_2
e_1_3_4_90_2
e_1_3_4_50_2
e_1_3_4_79_2
e_1_3_4_12_2
e_1_3_4_33_2
e_1_3_4_58_2
e_1_3_4_54_2
Wilcox CS (e_1_3_4_86_2) 1990; 38
e_1_3_4_10_2
e_1_3_4_31_2
e_1_3_4_75_2
e_1_3_4_16_2
e_1_3_4_37_2
e_1_3_4_77_2
e_1_3_4_14_2
e_1_3_4_35_2
e_1_3_4_56_2
e_1_3_4_18_2
e_1_3_4_39_2
Wilcox CS (e_1_3_4_87_2) 1993; 6
References_xml – ident: e_1_3_4_18_2
  doi: 10.1177/1358836X0501000106
– ident: e_1_3_4_49_2
  doi: 10.1016/j.vph.2005.09.005
– ident: e_1_3_4_62_2
  doi: 10.1161/01.CIR.99.24.3092
– ident: e_1_3_4_17_2
  doi: 10.1177/1358836X0501000104
– ident: e_1_3_4_71_2
  doi: 10.1093/eurheartj/ehp061
– ident: e_1_3_4_58_2
  doi: 10.1021/bi702377a
– ident: e_1_3_4_85_2
  doi: 10.1093/ajh/3.3.242
– volume: 6
  start-page: 124
  year: 1993
  ident: e_1_3_4_87_2
  article-title: Vasoconstrictor prostaglandins in angiotensin-dependent and renovascular hypertension
  publication-title: J Nephrol
– ident: e_1_3_4_27_2
  doi: 10.1016/j.pharmthera.2010.01.003
– volume: 38
  start-page: S81
  year: 1990
  ident: e_1_3_4_86_2
  article-title: Angiotensin II and thromboxane in the regulation of blood pressure and renal function
  publication-title: Kidney Int
– ident: e_1_3_4_23_2
  doi: 10.1161/hypertensionaha.111.170472
– ident: e_1_3_4_65_2
  doi: 10.1038/sj.ki.5001983
– ident: e_1_3_4_80_2
  doi: 10.1152/ajpheart.00134.2002
– ident: e_1_3_4_15_2
  doi: 10.2337/diacare.27.3.765
– ident: e_1_3_4_74_2
  doi: 10.1161/circresaha.107.158915
– ident: e_1_3_4_47_2
  doi: 10.1172/JCI200314172
– ident: e_1_3_4_50_2
  doi: 10.1093/cvr/cvq366
– ident: e_1_3_4_21_2
  doi: 10.1152/ajpheart.00998.2007
– ident: e_1_3_4_4_2
  doi: 10.1016/0006-291X(87)90929-6
– ident: e_1_3_4_32_2
  doi: 10.1042/CS20050307
– ident: e_1_3_4_75_2
  doi: 10.1161/atvbaha.110.222638
– ident: e_1_3_4_78_2
  doi: 10.1161/01.HYP.38.3.655
– ident: e_1_3_4_26_2
  doi: 10.1124/pr.108.000240
– ident: e_1_3_4_8_2
  doi: 10.1016/S0091-679X(08)60010-2
– ident: e_1_3_4_52_2
  doi: 10.1016/j.freeradbiomed.2008.08.013
– ident: e_1_3_4_3_2
  doi: 10.1016/0003-9861(87)90060-9
– ident: e_1_3_4_40_2
  doi: 10.1161/01.cir.0000093661.90582.c4
– ident: e_1_3_4_46_2
  doi: 10.1016/j.jacc.2008.04.019
– ident: e_1_3_4_19_2
  doi: 10.1002/cbic.200500527
– ident: e_1_3_4_29_2
  doi: 10.1172/JCI118623
– ident: e_1_3_4_82_2
  doi: 10.1056/NEJMoa013591
– ident: e_1_3_4_9_2
  doi: 10.1038/ncpneph0143
– ident: e_1_3_4_10_2
  doi: 10.1006/niox.1996.0106
– ident: e_1_3_4_44_2
  doi: 10.1161/01.hyp.0000156746.25300.1c
– ident: e_1_3_4_7_2
  doi: 10.1161/01.atv.0000128897.54893.26
– ident: e_1_3_4_33_2
  doi: 10.1152/ajprenal.00423.2003
– ident: e_1_3_4_90_2
  doi: 10.1016/j.freeradbiomed.2007.06.019
– ident: e_1_3_4_43_2
  doi: 10.1152/ajpheart.1986.250.5.H822
– ident: e_1_3_4_63_2
  doi: 10.2337/db06-1772
– ident: e_1_3_4_60_2
  doi: 10.1161/circresaha.107.156901
– ident: e_1_3_4_28_2
  doi: 10.1161/01.RES.80.1.45
– ident: e_1_3_4_54_2
  doi: 10.1097/01.ASN.0000090747.59919.D2
– ident: e_1_3_4_41_2
  doi: 10.1007/s11906-011-0187-x
– ident: e_1_3_4_72_2
  doi: 10.1093/ndt/17.11.1999
– ident: e_1_3_4_6_2
  doi: 10.1097/00005344-199204002-00018
– ident: e_1_3_4_88_2
  doi: 10.1248/bpb.28.641
– ident: e_1_3_4_30_2
  doi: 10.1016/S0165-6147(03)00233-5
– ident: e_1_3_4_45_2
  doi: 10.1172/JCI118935
– ident: e_1_3_4_16_2
  doi: 10.1161/01.CIR.98.18.1842
– ident: e_1_3_4_37_2
  doi: 10.1016/j.freeradbiomed.2011.06.011
– ident: e_1_3_4_69_2
  doi: 10.1111/j.1523-1755.2005.00392.x
– ident: e_1_3_4_67_2
  doi: 10.1152/ajpheart.01103.2007
– ident: e_1_3_4_59_2
  doi: 10.1159/000103284
– ident: e_1_3_4_35_2
  doi: 10.1053/j.ajkd.2007.09.020
– ident: e_1_3_4_39_2
  doi: 10.1161/ATVBAHA.108.181610
– ident: e_1_3_4_76_2
  doi: 10.1074/jbc.M109.037036
– ident: e_1_3_4_11_2
  doi: 10.1046/j.1365-2362.2003.01150.x
– ident: e_1_3_4_24_2
  doi: 10.1161/01.hyp.0000259669.40991.1e
– ident: e_1_3_4_51_2
  doi: 10.1089/ars.2006.8.1597
– ident: e_1_3_4_70_2
  doi: 10.1161/hypertensionaha.110.157115
– ident: e_1_3_4_56_2
  doi: 10.1016/j.freeradbiomed.2009.07.006
– ident: e_1_3_4_20_2
  doi: 10.1016/j.phrs.2009.08.002
– ident: e_1_3_4_64_2
  doi: 10.1016/S0895-7061(02)02278-1
– ident: e_1_3_4_2_2
  doi: 10.1016/S0021-9258(18)62716-4
– ident: e_1_3_4_83_2
  doi: 10.1161/hypertensionaha.109.135426
– ident: e_1_3_4_48_2
  doi: 10.1161/01.RES.87.2.99
– ident: e_1_3_4_12_2
  doi: 10.1046/j.1523-1755.2002.00437.x
– ident: e_1_3_4_42_2
  doi: 10.1038/hr.2010.201
– ident: e_1_3_4_13_2
  doi: 10.1016/S0140-6736(01)07217-8
– ident: e_1_3_4_22_2
  doi: 10.1161/01.res.0000129578.76799.75
– ident: e_1_3_4_53_2
  doi: 10.1161/01.hyp.0000200023.02195.73
– ident: e_1_3_4_57_2
  doi: 10.1038/sj.ki.5000067
– ident: e_1_3_4_68_2
  doi: 10.1152/ajpheart.00626.2004
– ident: e_1_3_4_73_2
  doi: 10.1093/ndt/gfg452
– ident: e_1_3_4_89_2
  doi: 10.1111/j.1476-5381.2009.00259.x
– ident: e_1_3_4_55_2
  doi: 10.1161/hypertensionaha.110.152959
– ident: e_1_3_4_81_2
  doi: 10.1007/s10157-008-0034-9
– ident: e_1_3_4_34_2
  doi: 10.1161/01.RES.0000020404.01971.2F
– ident: e_1_3_4_79_2
  doi: 10.1161/01.hyp.0000158262.11935.d0
– ident: e_1_3_4_31_2
  doi: 10.1161/01.hyp.0000154365.30593.d3
– ident: e_1_3_4_61_2
  doi: 10.1111/j.1523-1755.2000.00380.x
– ident: e_1_3_4_84_2
  doi: 10.1161/01.hyp.0000052945.84627.8f
– ident: e_1_3_4_36_2
  doi: 10.1152/ajpregu.90506.2008
– ident: e_1_3_4_5_2
  doi: 10.1016/S0021-9258(18)81786-0
– ident: e_1_3_4_77_2
  doi: 10.1016/j.bbrc.2004.01.120
– ident: e_1_3_4_14_2
  doi: 10.1038/sj.ki.5000417
– ident: e_1_3_4_38_2
  doi: 10.1161/hypertensionaha.109.142422
– ident: e_1_3_4_66_2
  doi: 10.1152/ajpregu.90875.2008
– ident: e_1_3_4_25_2
  doi: 10.1152/ajpregu.00250.2005
SSID ssj0014447
Score 2.3380466
SecondaryResourceType review_article
Snippet Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or...
SourceID proquest
pubmed
pascalfrancis
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 375
SubjectTerms Animals
Arginine - analogs & derivatives
Arginine - metabolism
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - metabolism
Cardiovascular Diseases - physiopathology
Disease Models, Animal
Endothelium, Vascular - physiopathology
Experimental diseases
Humans
Kidney Diseases - epidemiology
Kidney Diseases - metabolism
Kidney Diseases - physiopathology
Medical sciences
Rats
Reactive Oxygen Species - metabolism
Risk Factors
Title Asymmetric Dimethylarginine and Reactive Oxygen Species: Unwelcome Twin Visitors to the Cardiovascular and Kidney Disease Tables
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004268-201202001-00003
https://www.ncbi.nlm.nih.gov/pubmed/22215715
https://www.proquest.com/docview/918035994
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKkBASQvwc5cfkB96qlCaxk5i3qhsqjG0gtVCeosSxUUSXTmurrjzxF_A3cxe7bVKKGLxEVVQ7Se_r-b7L5ztCXko3jJIwDRwIJUKHuQl3koQxh2dpojwWdnRZnf_kNOgP2bsRHzUaPyuqpfksbcvvO_eV_I9V4RzYFXfJ_oNl15PCCfgM9oUjWBiO17Jxd7o8P8eWWBJcF_aCXgJP_YotH5TdeJiU7qx1drWESUyzeSOCGxYLNYZ7Uq3BIi9an_JpXvbdsaFory5TxcmO86wAB3Jo3ui0BrjnalqNbftAaS9LQXyJqOgQc_RGhaSu2i1XhKKSd_j89n3vbLRV38AmYm0WAuUcNUXHrmoSZRYiH6PUp5rAFAwd7KjqgW1N8LxChI079U1XFbsy-6a5y-9OP0Cn3__y4QgowCmuQd1-F9eCthuFvlXN1iptb62Aa10ismUfKOMNctMD2oF-8_jj5q0UY8xuvzfPYIvYwvVf_fnqtYDnzgUYLhlr0zRlF6uB7ywmKJSYfiv3SVSincE9ctfSFNo1mLtPGqp4QG6dWCHGQ_JjAz26DT0KaKEr6FEDPWqh95qugUcReHQFPDqbUAAerQOvnMoAj1rgUQO8R2T45mjQ6zu2mYcjfYH9AjMtPZEwDwm4ZlnWiTT4f8611FpGvKOYl0mZ8iQNIq0Drj0R8DTTgkdBoKT_mOwVk0I9IVSFYeprpoWWnGUyTSNg3VJkUcZlwl3dJGL1i8fSVrrHhivjuGS8gRtvWQtpcGys1ST-euyFqfdyrVEHNcOuh64A1SR0ZekY_De-lEsKNZlPY-FGWEVTsCbZNwjYDPYgHg9dGOzUIBGbLdJxye-9AH2i63WMOBJzHE__djfPyO3Nf_g52ZtdztULiK1n6UEJ-F_6WM6l
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Asymmetric+Dimethylarginine+and+Reactive+Oxygen+Species%3A+Unwelcome+Twin+Visitors+to+the+Cardiovascular+and+Kidney+Disease+Tables&rft.jtitle=Hypertension+%28Dallas%2C+Tex.+1979%29&rft.au=WILCOX%2C+Christopher+S&rft.date=2012-02-01&rft.pub=Lippincott+Williams+%26+Wilkins&rft.issn=0194-911X&rft.volume=59&rft.issue=2&rft.spage=375&rft.epage=381&rft_id=info:doi/10.1161%2FHYPERTENSIONAHA.111.187310&rft.externalDBID=n%2Fa&rft.externalDocID=25493495
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0194-911X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0194-911X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0194-911X&client=summon